ClinicalTrials.gg
TerminatedNCT06006143HARPUpdated Nov 6, 2026

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

A Phase 2 interventional study of Varenicline in Alcohol Use Disorder, Hiv and Tobacco Use Disorder, sponsored by Yale University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
recruitment challenges
Updated Nov 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing varenicline in Alcoholism — none open to participants now, none under way, none of them phase 3. Varenicline · Alcoholism.

Enrollment
15th of 16
3 · median 44
Started
2025
the only one that year
Phase 2
10 of 16
none open now
Registered
16th of 16
by date
Lead sponsor
2 of 16
Yale University

Among the 16 studies testing varenicline in Alcoholism, this one is the 15th largest by enrollment, is the only one that started in 2025, is one of 10 in phase 2, and was the 16th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 16 studies testing varenicline in Alcoholism is open now. The open studies under Alcoholism, anywhere →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing varenicline in Alcoholism as a file.
02

Study summary

This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.

Read the detailed description

This is a series of three open-label pilot studies that consist of a 12-week intervention including off-label use of medication with MM and a clinical pharmacist-delivered behavioral intervention to treat AUD. Participants will receive counseling that incorporates brief feedback and advice with motivational enhancement techniques to assist the participant in changing their behaviors with respect to alcohol consumption and/or polypharmacy defined as taking five or more medications, particularly if those medications interact with alcohol. In addition, participants will be offered varenicline in the first pilot study. The rationale for utilizing an open-label pilot study design is to determine the feasibility, acceptability, safety, and preliminary efficacy of this intervention for the management of AUD. Participants will be interviewed with regards to their perspectives on feasibility and acceptability. They will be instructed to have medication bottles at study visits to assess medication adherence and will be assessed with readiness to change metrics and questions regarding quantity and frequency of alcohol use. Patients will also be asked to complete an AUDIT-C screen and the Alcohol Symptom Checklist at the start of the study period to screen for mild, moderate, or severe AUD. Several assessments including interviews and laboratory testing will be done at study visits.

03

Conditions studied

  • Alcohol Use Disorder
  • Hiv
  • Tobacco Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with
  • Receive care at the Atlanta VA Healthcare System
  • Are age 18 or over
  • Meet criteria for mild, moderate, or severe alcohol use disorder by the Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
  • Have evidence of significant alcohol use: PEth > 20ng/ml
  • Currently smoking cigarettes
  • Prescribed >=5 medications
  • Have cell phone or reliable contact number
  • Can provide written

Exclusion criteria

Exclusion Criteria:

  • Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
  • Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
  • Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment
  • Untreated moderate to severe opioid use disorder
  • Residence out of state
  • Inability to read or understand English
  • History of serious or adverse reaction to study medication
  • Taking potentially interactive medication(s) (e.g. nicotine replacement therapy for varenicline pilot study)
  • Already prescribed the pilot medication at the time of study recruitment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Varenicline

    Participants will receive a prescription for generic varenicline

    Drug: Varenicline

Interventions

  • All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support

06

What researchers measure

Primary outcomes

  1. Proportion of participants who complete enrollment and duration of sessions

    Proportion of participants who complete enrollment and duration of sessions to assess feasibility of study

    Time frame: 12 weeks

  2. Number of sessions completed

    Number of sessions completed to assess acceptability of study

    Time frame: 12 weeks

  3. Adherence to Medication

    Medication adherence will be measured by the number of prescriptions filled by electronic health record to assess acceptability of study

    Time frame: 12 weeks

  4. Safety of study assessed by adverse events reporting

    Safety will be assessed by the percentage of study participants who report adverse events

    Time frame: 12 weeks

Secondary outcomes

  1. Efficacy of study - change in self-reported alcohol use

    Change in self-reported alcohol use (# of days of alcohol use and # of drinks per day) on the Timeline Followback.

    Time frame: 12 weeks

  2. Efficacy of study - change in PEth (phosphatidylethanol) results

    PEth is a biomarker for alcohol consumption. Change in PEth result from baseline PEth levels.

    Time frame: 12 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Aug 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 23, 2023
StartActual
Jun 16, 2025
Primary completionActual
Aug 5, 2026
CompletionActual
Aug 5, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated recruitment challenges
changed Nov 6, 2026
Primary completion
Aug 31, 2026→Aug 5, 2026 (actual)
Nov 6, 2026
Study completion
Aug 31, 2026→Aug 5, 2026 (actual)
Nov 6, 2026
Enrollment
30 (estimated)→3 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Terminated
    Why stopped recruitment challenges
    Primary completion Aug 31, 2026→Aug 5, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 5, 2026 (now actual)
    Enrollment 30 (estimated)→3 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06006143
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Jun 16, 2025
Primary completion
Aug 5, 2026
Completion
Aug 5, 2026
Last update
Nov 6, 2026

Study contacts

E. Jennifer Edelman, MD, MHS
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion